Maker Of Pain-Monitoring Device Inks Deal For Distribution In Japan

Israeli medtech startup Medasense has entered a strategic partnership with top Japanese manufacturer of medical electronics Nihon Kohden for exclusive distribution of its novel pain-monitoring device in Japan.

Medasense’s flagship PMD-200 device incorporates the company’s state-of-the-art, AI-powered Nociception Level Index (NOL) to provide real-time pain monitoring, enabling treatment to be personalized and optimized. 

Pending regulatory approval, the device will be available in hospitals and clinics across Japan via Nihon Kohden’s distribution channels.  

NOL monitoring provides a clinically validated index to objectively quantify the physiological response to pain (nociception), helping clinicians to deliver anesthesia options tailored to the needs of individual patients. 

The device has been peer-reviewed in more than 40 publications, and clinical studies showed that NOL-guided pain relief led to less use of opioids during surgery and better patient recovery, including postoperative pain scores. 

It is the only pain monitor to receive authorization from the US Food and Drug Administration (FDA) to measure pain for anesthesiology. It is marketed in Europe, Israel, Latin America and North America, and has been used in more than 100,000 surgeries worldwide. 

“We are honored to partner with Nihon Kohden, a company with a long history of excellence, that shares our vision of improving patient care through innovative solutions,” said Medasense founder and CEO Galit Zuckerman. 

“Our mission is to help all patients suffer less from pain and the adverse effects of pain medication. Nihon Kohden’s established clinical, technological leadership and expertise in the Japanese market make them the perfect partner to distribute our nociception monitor,” she said.